ALMS Alumis Inc.
QT11Latest market price
6.73
-0.16-2.32%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.92 | Insider Own | 34.92% | Shs Outstand | 129.44M | Perf Week | -0.74% |
| Market Cap | 871.10M | Forward P/E | — | EPS next Y | -2.82 | Insider Trans | 1.93% | Shs Float | 91.34M | Perf Month | -6.66% |
| Enterprise Value | 401.10M | PEG | — | EPS next Q | -0.73 | Short Float | 12.13% | Perf Quarter | -74.23% | ||
| Income | -243.00M | P/S | 36.30 | EPS this Y | — | Short Ratio | 4.40 | Perf Half Y | -73.27% | ||
| Sales | 24.00M | P/B | 1.93 | EPS next Y | — | ROA | -78.30% | Short Interest | 11.08M | Perf YTD | -31.05% |
| Book/sh | 3.49 | P/C | 1.74 | EPS next 5Y | — | ROE | -102.97% | 52W High | 31.35 -78.53% | Perf Year | 42.89% |
| Cash/sh | 3.88 | P/FCF | — | EPS past 3/5Y | — | ROIC | -93.45% | 52W Low | 4.39 53.30% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 88.23% | Volatility | 7.27% 6.13% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 16.71 | EPS Y/Y TTM | — | Oper. Margin | -6204.39% | ATR (14) | 0.53 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 6.74 | Sales Y/Y TTM | -60.00% | Profit Margin | -5933.45% | RSI (14) | 37.34 | Recom | 2.13 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.74 | EPS Q/Q | 5.13% | SMA20 | 0.35% | Beta | 1.76 | Target Price | 29.57 |
| Payout | 0.00% | Debt/Eq | 0.07 | Sales Q/Q | -33.33% | SMA50 | -31.74% | Rel Volume | 0.83 | Prev Close | 6.89 |
| Employees | 237 | LT Debt/Eq | 0.07 | Earnings | Nov 12 | SMA200 | -68.58% | Avg Volume | 2.69M | Price | 6.73 |
| IPO Date | Jun 28, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -44.72% -54.49% | Net Debt/EBITDA | — | Volume | 2,236,875 | Change | -2.32% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-03-26 | Downgrade | Guggenheim | Buy → Neutral | |
| Sep-02-26 | Upgrade | HC Wainwright & Co. | Neutral → Buy | $25 → $15 |
| Sep-02-26 | Reiterated | Morgan Stanley | Overweight | $39 → $29 |
| Sep-02-26 | Reiterated | Oppenheimer | Outperform | $50 → $37 |
| Sep-01-26 | Reiterated | Robert W. Baird | $35 → $27 | |
| May-19-26 | Reiterated | Chardan Capital | Buy | $37 → $40 |
| May-15-26 | Reiterated | Morgan Stanley | Overweight | $38 → $39 |
| May-15-26 | Reiterated | Guggenheim | Buy | $32 → $34 |
| May-15-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $40 → $25 |
| May-15-26 | Reiterated | Wells Fargo | Overweight | $39 → $51 |
Latest News· Times ET
Oct-12-26
Oct-12-2602:15AM
Oct-09-26
Oct-09-2601:11PM
04:00AM
Oct-06-26
Oct-06-2603:17AM
Sep-16-26
Sep-16-2601:29AM
Sep-15-26
Sep-14-26
Sep-14-2610:41AM
Sep-08-26
Sep-08-2609:30PM
Sep-05-26
Sep-05-2603:48AM
Sep-04-26
Sep-04-2603:07PM
08:00AM
Alumis to Participate in Upcoming September Investor Conferencesglobenewswire.com
Sep-01-26
03:00PM
12:24PM
11:03AM
Company
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 24 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 3 | 3 | 0 | — | |
| Gross Profit | 21 | -3 | 0 | — | |
| Selling, General and Administrative Excl. Other | 92 | 35 | 20 | — | |
| Research and Development | 386 | 266 | 138 | — | |
| Other Operating Expense | -30 | -3 | 0 | — | |
| Operating Income | -427 | -301 | -158 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 175 | 7 | 3 | — | |
| Net Income Before Taxes | -252 | -294 | -155 | — | |
| Income Taxes | -9 | 0 | 0 | — | |
| Consolidated Net Income | -243 | -294 | -155 | — | |
| Net Income From Continuing Operations | -243 | -294 | -155 | — | |
| Net Income | -243 | -294 | -155 | — | |
| EPS (Recurring) | -2.32 | -10.38 | -2.99 | — | |
| EPS (Basic, Before Extraordinaries) | -2.32 | -10.38 | -2.99 | — | |
| EPS (Diluted) | -2.32 | -10.38 | -2.99 | — | |
| EBITDA | -248 | -291 | -154 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | 345.67 | — | — | — | |
| Gross Margin | 87.50 | — | — | — | |
| Operating Margin | -1,779.17 | — | — | — | |
| Net Margin | -1,012.50 | — | — | — | |
| Shares Outstanding | 850 | 28 | 52 | — | |
| Market Capitalization | 8,296 | 220 | — | — | |
| Operating Lease Expense | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Sep 08 '26 | Sale | 10.55 | 96,131 | 1,014,028 | 2,025,493 | Sep 09 |
| AKKARAJU SRINIVAS | Director | Sep 08 '26 | Buy | 10.63 | 546,581 | 5,808,571 | 4,937,026 | Sep 09 |
| AKKARAJU SRINIVAS | Director | Sep 04 '26 | Buy | 11.17 | 440,140 | 4,917,684 | 4,711,801 | Sep 09 |
| Schroer John R. | Chief Financial Officer | Aug 03 '26 | Sale | 26.37 | 3,282 | 86,546 | 24,718 | Aug 05 |
| Goldstein David M | Chief Scientific Officer | Aug 03 '26 | Sale | 26.37 | 2,596 | 68,457 | 30,970 | Aug 05 |
| Drappa Jorn | Chief Medical Officer | Aug 03 '26 | Sale | 26.37 | 2,447 | 64,527 | 56,892 | Aug 05 |
| Pangali Sanam | Chief Legal Officer | Aug 03 '26 | Sale | 26.37 | 1,364 | 35,969 | 9,747 | Aug 05 |
| Bradley Mark Christopher | Chief Development Officer | Aug 03 '26 | Sale | 26.37 | 2,572 | 67,824 | 48,533 | Aug 05 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr | Aug 03 '26 | Sale | 26.37 | 2,692 | 70,988 | 207,746 | Aug 05 |
| Pangali Sanam | Chief Legal Officer | Jul 06 '26 | Sale | 28.00 | 5,000 | 140,000 | 11,111 | Jul 08 |
| Pangali Sanam | Chief Legal Officer | Jul 06 '26 | Option Exercise | 5.06 | 5,000 | 25,300 | 16,111 | Jul 08 |
| Drappa Jorn | Chief Medical Officer | May 22 '26 | Option Exercise | 6.65 | 26,852 | 178,649 | 59,339 | May 27 |
| AKKARAJU SRINIVAS | Director | Jan 09 '26 | Buy | 17.00 | 588,235 | 9,999,995 | 1,853,488 | Jan 13 |
| Foresite Labs, LLC | 10% Owner | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 |
| Foresite Capital Management VI LLC | 10% Owner | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.